Feasibility of Intraoperative Tracing of Meningioma Using [Cu64]DOTATATE
Part of paid clinical trials in New York, New York.
- Sponsor
- Weill Medical College of Cornell University
- Study ID
- NCT06377371
- Phase
- PHASE4
- Status
- Recruiting
Conditions
- Meningioma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 99 Years
- Healthy Volunteers
- Not accepted
Interventions
- Brain Imaging with [Cu64]DOTATATE — DIAGNOSTIC_TESTPatients will undergo a \[Cu64\]DOTATATE PET/MRI or PET/CT before undergoing radio- guided surgery. Patients will undergo another \[Cu64\]DOTATATE PET/MRI or PET/CT 6 weeks- 3 months after their surgery, and 6 months- 12 months after surgery.
- Radio-guided Surgery With Neoprobe Utilization — PROCEDUREAfter the subjects undergo the preoperative \[Cu64\]DOTATATE PET/MRI, subjects will undergo radio-guided surgery in which the surgeon will utilize a standard intraoperative gamma probe (Neoprobe Gamma Detection System ®) to assess primary/residual tumor detection.
Study Details
The study team hypothesizes that it is feasible to intraoperatively detect tumor following \[CU64\]DOTATATE injection using the gamma probe device.
Key Dates
- Start date
- Sep 11, 2024
- Status verified
- Feb 2026
- Primary completion
- Jan 31, 2027
- Completion
- Jan 31, 2027
Study Design
- Enrollment
- 20 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Patients with MRI findings compatible with meningioma who have an indication for surgeryA diagnostic intervention in which patients will undergo intraoperative meningioma tracing using \[Cu64\]DOTATATE.
Primary Outcome Measure
Preoperative [Cu64]DOTATATE PET SUV [ Time Frame: At time of enrollment ]
Central Contacts
- Jana Ivanidze, MD/PhD212-746-4587
- Alexis Watson646-962-2347
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| New York-Presbyterian/Weill Cornell Medical Center | New York | New York | 10021 | Jana Ivanidze, MD/PhD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in New York, NY
By research site
Related Studies
- 68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.PHASE4 · Recruiting · Weill Medical College of Cornell University · New York, New York
- Direct Comparison of Ga-68-DOTATATE and Ga-68-DOTATOCPHASE2 · Not Yet Recruiting · Weill Medical College of Cornell University · New York, New York
- Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)PHASE2 · Recruiting · Scott R. Plotkin, MD, PhD · Los Angeles, California
- Cabozantinib for Patients With Recurrent or Progressive MeningiomaPHASE2 · Recruiting · Baptist Health South Florida · Miami, Florida